CervoMed Inc.

Contributing Author

Recent Articles by CervoMed Inc.

Nov-10	CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates CRVO GlobeNewswire
Nov-04	CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies CRVO GlobeNewswire
Oct-28	CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley CRVO GlobeNewswire
Oct-20	CervoMed to Present at the Emerging Growth Conference CRVO GlobeNewswire
Oct-08	CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies CRVO GlobeNewswire
Oct-07	CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer CRVO GlobeNewswire
Oct-02	CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference CRVO GlobeNewswire
Sep-17	CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference CRVO GlobeNewswire
Sep-03	CervoMed to Participate in Upcoming Investor Conferences CRVO GlobeNewswire
Aug-11	CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates CRVO GlobeNewswire
Aug-05	CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference CRVO GlobeNewswire
Jul-28	CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration CRVO GlobeNewswire
Jul-24	CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025 CRVO GlobeNewswire
Jul-08	CervoMed Announces Late-Breaking Presentations at Alzheimer's Association International Congress 2025 CRVO GlobeNewswire
Jun-10	CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization CRVO GlobeNewswire
May-12	CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates CRVO GlobeNewswire
May-07	CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference CRVO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.